Five-year outcomes demonstrate HAV retained durability and structural integrity, potentially offering a safe and viable option for long-term hemodialysis Long-term explant samples demonstrate progressive host cell remodeling to create living vascular tissue; no indication of rejection of HAV ...
DURHAM, N.C., April 14, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the closing of a secured debt financing facility with Silicon Valley Bank for up to $50...
DURHAM, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Rajiv Shukla, Alpha...
DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the clinical results of five-year outcomes in patients receiving the human...
Humacyte aims to transform medicine with off-the-shelf, universally implantable, bioengineered human tissue available at commercial scale. Transaction values Humacyte at a pre-money valuation of $800 million with existing Humacyte shareholders rolling over 100% of their equity into equity of the...
Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that President and CEO Laura Niklason, M.D., Ph.D. will present virtually at the ICR Conference on January 14 at 12:15 p.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative...
DURHAM, N.C., Jan. 11, 2021 /PRNewswire/ -- Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason, M.D., Ph.D. will present virtually at the 39 th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST. Dr....
DURHAM, N.C., Dec. 9, 2020 /PRNewswire/ -- Humacyte President and CEO Laura Niklason, M.D., Ph.D. will speak at the renowned Milken Institute Future of Health Summit on Wednesday, December 9 at 1:30 p.m. EST. Laura E. Niklason, MD Humacyte, Inc In a session entitled Bringing It All Together:...
Jeffrey Lawson MD, PhD Appointed Chief Surgical Officer and Vice Chairman, to Enhance Product Positioning and Clinical Adoption Business Wire DURHAM, N.C. -- November 20, 2020 Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Laura Niklason MD, PhD has been...
DURHAM, N.C., Oct. 9, 2020 /PRNewswire/ -- A new manuscript published in the highly cited scientific journal Science (also known as Science Magazine ) reveals great strides in the field of regenerative medicine and vascular tissue engineering. Humacyte, Inc....
